
SABCS 2018: Liquid biopsies in SOLAR-1 trial predict benefit of alpelisib in PIK3CA-mutant breast cancer
Liquid biopsy-based assessment of PIK3CA mutational status served as a better indicator of progression-free survival…
Liquid biopsy-based assessment of PIK3CA mutational status served as a better indicator of progression-free survival…